USP9X and endometrial carcinoma: USP9X mutations have been identified in several cancer types at significant levels in the TCGA studies: 11% of endometrial carcinoma, 9% of stomach adenocarcinoma and 9% of head and neck squamous cell carcinomas (cBioportal) [28].